ImmunityBio, Inc. (IBRX) shares surged over 35% today to $5.34, marking a massive breakout for the immunotherapy company. This rally follows a 28% jump on January 15, driven by preliminary full-year 2025 net product revenue of approximately $113 million.
The two-day move represents a significant turnaround for the stock, as various market factors have contributed to a gain of nearly 147% over the last month.
| Current Price | $5.34 |
| Daily Change | +35.06% 🟢 |
| Day Range | $4.39 – $5.55 |
| 52-Week Range | $1.83 – $5.55 |
The immediate catalyst is a combination of explosive revenue growth and landmark international regulatory wins. According to financial data, the company reported a 700% year-over-year increase in preliminary 2025 revenue.
This momentum is further bolstered by accelerated approvals from the Saudi Food and Drug Authority (SFDA) for its primary therapeutic, ANKTIVA.
Investors are reacting to what appears to be a multi-faceted expansion strategy. While the broader biotechnology industry average rose only about 1.5% today, IBRX dramatically outperformed peers like Structure Therapeutics and Celldex Therapeutics.
| Company | Symbol | Daily Change | Market Cap |
|---|---|---|---|
| ImmunityBio | IBRX | +35.06% 🟢 | N/A |
| RAPT Therapeutics | RAPT | +7.08% | N/A |
| Structure Therapeutics | GPCR | +4.49% | N/A |
| Celldex Therapeutics | CLDX | +1.64% | N/A |
| Inhibrx Biosciences | INBX | +0.97% | N/A |
| Industry Avg | – | +1.54% | – |
*Market capitalization data not available in source.
Key Takeaways
- Preliminary 2025 net product revenue reached $113 million, a 700% increase over 2024.
- The Saudi FDA granted two accelerated approvals for ANKTIVA in lung and bladder cancer.
- Clinical trial updates show a 100% disease control rate in a new lymphoma study.
- Average analyst price targets have increased over 10% to a new estimate of $11.73.
- Institutional ownership rose nearly 14% in the most recent quarter.
ImmunityBio (IBRX) Stock Explodes 35% – What Happened Today?
Today's move is the culmination of a high-velocity news cycle that began earlier this week. The stock opened the week at $2.82 and has since climbed to an intraday high of $5.55, which also represents its new 52-week high.
This price action, often tracked by investors who know how to read stock charts, is supported by strong preliminary fourth-quarter 2025 revenue of $38.3 million, which grew 20% sequentially from the third quarter.
The revenue growth is largely attributed to ANKTIVA, which saw unit sales grow approximately 750% in 2025 compared to the previous year.
President and CEO Richard Adcock noted that the results reflect the accelerating adoption of the therapy and the successful execution of the company’s commercial strategy. ImmunityBio also reported a solid cash position, ending the year with an estimated $242.8 million.
What Catalysts Are Driving IBRX's Multi-Faceted Rally?
Regulatory milestones in Saudi Arabia have provided a major tailwind for the stock this week. The SFDA granted accelerated approval for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC).
This is the world’s first approval for an IL-15 superagonist in this specific combination and indication.
Additionally, the SFDA approved ANKTIVA plus Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive bladder cancer. Dr. Patrick Soon-Shiong, the company’s Executive Chairman, stated that these approvals are a meaningful milestone that could pave the way for additional authorizations across the Middle East.
Beyond Approvals: IBRX's Advancing Clinical Pipeline
ImmunityBio also released positive data from its QUILT-106 clinical study today. The company reported that its chemotherapy-free CD19 CAR-NK cell therapy achieved durable complete responses of 7 and 15 months in patients with Waldenström Non-Hodgkin Lymphoma.
Across the initial four subjects, the trial demonstrated a 100% disease control rate.
Progress is also accelerating in the company’s registrational trials. The QUILT-2.005 trial for BCG-naïve bladder cancer is now over 85% complete.
Interim analysis showed that combining ANKTIVA with BCG resulted in an 84% response rate at nine months, significantly higher than the 52% seen with BCG alone.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | +146.76% | 🟢 |
| 3 Months | +110.67% | 🟢 |
| 6 Months | +93.82% | 🟢 |
| 1 Year | +123.01% | 🟢 |
What Are Analysts Saying About ImmunityBio's Future?
Wall Street sentiment has turned increasingly bullish following these developments. While stock sentiment analysis remains mixed among some observers, data from Nasdaq via Fintel shows the average one-year price target for IBRX has increased over 10% to $11.73.
Some firms are even more aggressive, with D. Boral Capital reaffirming a “buy” rating and a $24.00 price objective.
Institutional interest is also on the rise. Data shows that 391 funds now report positions in ImmunityBio, an increase of about 5% last quarter.
Total institutional shares rose nearly 14% to 155,874K. However, the outlook is not universally positive, as Weiss Ratings currently maintains a “sell” rating on the stock, citing its clinical-stage risks and a negative P/E ratio of -6.88.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • 700% Y/Y Revenue Growth ($113M) | • Negative P/E Ratio of -6.88 |
| • Global Expansion & Saudi FDA Approvals | • Clinical-Stage Pipeline Risks |
| • Institutional Ownership up 14% | • Weiss Ratings “Sell” Recommendation |
IBRX's Strategic Alliances & Market Expansion
To support its global ambitions, ImmunityBio and NantWorks recently announced the inaugural U.S.-Saudi Biotech Alliance Summit. This alliance aims to advance “Immunotherapy 2.0,” focusing on next-generation NK and T-cell based treatments.
The company intends to open a regional office in Saudi Arabia to manage these efforts.
The company has also partnered with Biopharma Cigalah for distribution across the Middle East and North Africa. CEO Richard Adcock highlighted the “large and growing” cancer incidence in the region as a primary reason for this market expansion.
What Should Investors Watch Next for ImmunityBio (IBRX)?
Moving forward, investors should monitor the full enrollment of the QUILT-2.005 trial, which is expected by the second quarter of 2026. The company plans to file a Biologics License Application (BLA) for this indication by the end of 2026.
While the current rally is supported by strong revenue, market analysis and free stock research tools suggest that the stock's future performance will depend on the successful commercial launch in Saudi Arabia and the results of ongoing confirmatory trials.
The Bottom Line
ImmunityBio is currently outperforming the broader biotech sector as it transitions from a purely clinical-stage company to a commercial entity with international reach. The 700% revenue growth and landmark Saudi FDA approvals have provided a clear fundamental basis for the recent surge.
However, risks remain. The company’s small clinical cohorts and its negative P/E ratio suggest that volatility may continue.
Investors should weigh the significant analyst price targets against the inherent uncertainties of global regulatory expansions and early-stage clinical data.
